SGLT2 inhibitors (cuts approx. 400 kcal of sugar) - includes shipping and consultation fees

SGLT2 inhibitors are medications that improve blood sugar levels by expelling excess sugar into the urine.

They are said to expel approximately 200-400 kcal worth of sugar per day, and when used in conjunction with diet and exercise, they can also support weight loss.

When combined with diet and exercise, a greater weight loss effect can be expected.

We offer the following SGLT2 inhibitors at our clinic:

Suglat
Recommended for those who want to expel a large amount of sugar and expect a significant weight loss effect.

Canaglu
A medication with abundant evidence for both weight loss and blood sugar improvement.

Forxiga Generic (Dapagliflozin)
Chosen by those using SGLT2 inhibitors for the first time due to its relatively mild action.

Lusefi
Recommended for those who want to minimize side effects with its gentle action.

Take one tablet once a day, before or after breakfast.

The prices shown include consultation fees and medication costs.

Main side effects:

・Frequent urination
・Increased urine volume
・Thirst
・Dehydration
・Dizziness

Also, because sugar is excreted in the urine,

・Cystitis
・Itching of the external genitalia/genitals
・Candidiasis

and other urinary tract infections and genital infections may occur.

If you experience symptoms such as severe fatigue, nausea, or difficulty breathing, stop taking the medication and seek medical attention immediately.

・Drink plenty of fluids.
・If you experience dehydration due to fever, diarrhea, vomiting, etc., stop taking the medication and consult your doctor.
・Individuals on extreme carbohydrate restriction should exercise caution as there is an increased risk of ketoacidosis.
・If you develop a urinary tract infection or genital infection, consult your doctor.
・Do not take if you are pregnant or breastfeeding.

・Individuals with severe renal impairment
・Individuals undergoing dialysis
・Individuals with severe dehydration
・Individuals allergic to the ingredients of this drug
・Pregnant or breastfeeding individuals
・Individuals for whom a doctor has deemed unsuitable for taking this drug

At our clinic, you can choose between "Standard Delivery (Nekoposu)" or "Takkyubin Compact (+500 yen)," depending on the size of your package and your preferences.

Standard Delivery (Nekoposu)
Delivered via mailbox.
You can receive it even if you are not home.
Delivery date and time cannot be specified.

Takkyubin Compact (+500 yen)
Requires in-person receipt.
Delivery date and time can be specified.
Even after shipping, you can change the delivery date and time, or the pick-up location such as a sales office or convenience store.

For details on delivery methods, please refer to "About Delivery".

*Depending on your order details and the quantity of products, we may change to the most suitable delivery method at our clinic. In such cases, no additional shipping fees will be incurred.

・Unapproved drugs, etc. (use for different purposes)
Under the Pharmaceuticals and Medical Devices Act, this drug is approved for the efficacy and effect of type 2 diabetes. However, its use for obesity treatment at our clinic is not approved in Japan.

・Procurement route, etc.
We procure domestically approved drugs from domestic pharmaceutical wholesalers.

・Availability of domestically approved drugs
Although it is approved in Japan for the efficacy and effect of type 2 diabetes, the approved efficacy, effect, dosage, and administration differ from the purpose and method of use at our clinic.

〈About the drugs〉

Suglat・Name: Suglat Tablets
・Generic name: Ipragliflozin L-Proline
・Manufacturer and distributor: Astellas Pharma Inc.Canaglu・Name: Canaglu Tablets
・Generic name: Canagliflozin Hydrate
・Manufacturer and distributor: Mitsubishi Tanabe Pharma CorporationForxiga (Generic)・Name: Dapagliflozin Tablets
・Generic name: Dapagliflozin Propylene Glycol Hydrate
・Manufacturer and distributor: Sawai Pharmaceutical Co., Ltd.Lusefi・Name: Lusefi Tablets
・Generic name: Luseogliflozin Hydrate
・Manufacturer and distributor: Taisho Pharmaceutical Co., Ltd.